IDS and mucopolysaccharidosis type 2: The results are also in line with observations in localized studies of smaller numbers of IV idursulfase-treated patients, including one with 10 years of follow-up [13–16], and provide valuable support for these findings in a larger and more diverse population of patients with MPS II.